KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas

Journal of Gastrointestinal Oncology

Volumn 5, Issue 4, 2014, Pages 265-269

  Baskin, Yasemin ^a   Dagdeviren, Yusuf Kagan ^a   Calibasi, Gizem ^a   Canda, Aras Emre ^a   Sarioglu, Sulen ^a   Ellidokuz, Hulya ^a   Oztop, Ilhan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Colon cancer; KRAS mutations; Rectosigmoid cancer

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; CYSTEINE; GENOMIC DNA; GLYCINE; SERINE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CHI SQUARE TEST; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RECTOSIGMOID CANCER; TISSUE SECTION; TUMOR LOCALIZATION; TURKEY (REPUBLIC);

EID: 84995777942     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2014.038     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Kapiteijn E, Liefers GJ, Los LC, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001;195:171-8.
3. Slattery ML, Curtin K, Wolff RK, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009;52:1304-11.
4. Russo A, Rizzo S, Bronte G, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009;77 Suppl 1:57-68.
5. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-39.
6. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 2012;12:163-71.
7. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
8. Fujita S, Baba H, Yamamoto S, et al. Allelic status of chromosomes 17p, 18q, 22q [corrected] 3p and their clinical usefulness in colorectal cancer. Anticancer Res 2006;26:2833-40.
9. Soussi T. Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta 2011;1816:199-208.
10. Georgakopoulos G, Tsiambas E, Korkolopoulos P, et al. c-MYC and h-TERT co-expression in colon adenocarcinoma: a tissue microarray digitized image analysis. J BUON 2013;18:124-30.
11. Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54:374-84.
12. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004;22:4584-94.
13. Patil H, Korde R, Kapat A. KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. Med Oncol 2013;30:617.
14. Abubaker J, Bavi P, Al-Haqawi W, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009;219:435-45.
15. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
16. Watanabe T, Yoshino T, Uetake H, et al. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol 2013;43:706-12.
17. Derbel O, Wang Q, Desseigne F, et al. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. BMC Cancer 2013;13:200.
18. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50.
19. Jakovljevic K, Malisic E, Cavic M, et al. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON 2012;17:575-80.
20. Mao C, Zhou J, Yang Z, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 2012;7:e36653.